Role of rCBV values derived from dynamic susceptibility contrast-enhanced magnetic resonance imaging in differentiating CNS lymphoma from high grade glioma: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 12, 2014, Pages 5573-5577

  Liang, Ruofei ^a   Li, Mao ^a   Wang, Xiang ^a   Luo, Jiewen ^a   Yang, Yuan ^a   Mao, Qing ^a   Liu, Yanhui ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

CNS lymphoma; High grade glioma; Meta analysis; RCBV values

Indexed keywords

ARTICLE; BRAIN BLOOD FLOW; CENTRAL NERVOUS SYSTEM TUMOR; DISEASE CLASSIFICATION; GLIOMA; HUMAN; LYMPHOMA; META ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUSCEPTIBILITY WEIGHTED IMAGING;

EID: 84921464688     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Wong ET. Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities. Clin Cancer Res 2005; 11: 7151s-7157s.
2. Roth P, Korfel A, Martus P, Weller M. Pathoge-nesis and management of primary CNS lymphoma. Expert Rev Anticancer Ther 2012; 12: 623-633.
3. Villà S, Balañà C, Comas S. Radiation and concomitant chemotherapy for patients with glioblastoma multiforme. Chin J Cancer 2014; 33: 25-31.
4. Stupp R, Tonn JC, Brada M, Pentheroudakis G; ESMO Guidelines Working Group. High-grade malignant glioma: ESMO Clinical Practice Gui-delines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v190-v193.
5. Ma JH, Kim HS, Rim NJ, Kim SH, Cho KG. Dif-ferentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions. AJNR Am J Neu-roradiol 2010; 31: 1699-1706.
6. Herrlinger U, Schabet M, Clemens M, Kortmann RD, Petersen D, Will BE, Meyermann R, Dich-gans J. Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand 1998; 97: 257-264.
7. Reni M, Ferreri AJ, Garancini MP, Villa E. Thera-peutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997; 8: 227-234.
8. Kang Y, Choi SH, Kim YJ, Kim KG, Sohn CH, Kim JH, Yun TJ, Chang KH. Gliomas: histogram analysis of apparent diffusion coefficient maps with standard-or high-b-value diffusion-weighted MR imaging-correlation with tumor grade. Radiology 2011; 261: 882-890.
9. Lu S, Ahn D, Johnson G, Cha S. Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors. AJNR Am J Neu-roradiol 2003; 24: 937-941.
10. Howe FA, Barton SJ, Cudlip SA, Stubbs M, Sau-nders DE, Murphy M, Wilkins P, Opstad KS, Doyle VL, McLean MA, Bell BA, Griffiths JR. Me-tabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance sp-ectroscopy. Magn Reson Med 2003; 49: 223-232.
11. Svolos P, Tsolaki E, Kapsalaki E, Theodorou K, Fountas K, Fezoulidis I, Tsougos I. Investigating brain tumor differentiation with diffusion and perfusion metrics at 3T MRI using pattern recognition techniques. Magn Reson Imaging 2013; 31: 1567-1577.
12. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic revi-ews. BMC Med Res Methodol 2003; 3: 25.
13. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUA-DAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Me-thodol 2006; 6: 9.
14. Higgins J, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. B-MJ 2003; 327: 557-560.
15. Zamora J, Abraira V, Muriel A, Khan K, Cooma-rasamy A. Meta-DiSc: a software for meta-an-alysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.
16. Xing Z, You RX, Li J, Liu Y, Cao DR. Differentiation of Primary Central Nervous System Lymphomas from High-Grade Gliomas by rCBV and Per-centage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contra-st-Enhanced Perfusion MR Imaging. Clin Neu-roradiol 2013; 31: 1-8.
17. Toh CH, Wei KC, Chang CN, Ng SH, Wong HF. Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction. AJNR Am J Neuroradiol 2013; 34: 1145-1149.
18. Abul-Kasim K, Maly P, Strömbeck A, Svensson J, Sundgren PC. Perfusion weighted MR imaging may differentiate primary CNS-lymphoma from other homogeneously enhancing brain tumours. Neuroradiol J 2008; 21: 637-644.
19. Wang S, Kim S, Chawla S, Wolf RL, Knipp DE, Vossough A, O’Rourke DM, Judy KD, Poptani H, Melhem ER. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2011; 32: 507-514.
20. Coulon A, Lafitte F, Hoang-Xuan K, Martin-Duverneuil N, Mokhtari K, Blustajn J, Chiras J. Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol 2002; 12: 329-340.
21. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weig-hted echo-planar perfusion MR imaging. Ra-diology 2002; 223: 11-29.
22. Covarrubias DJ, Rosen BR, Lev MH. Dynamic magnetic resonance perfusion imaging of br-ain tumors. Oncologist 2004; 9: 528-537.